We are live on ! Find out more
ADAP

Adaptimmune Therapeutics
ADAP

Delisted

ADAP was delisted on the 27th of October, 2025.

Back to rankings

49 hedge funds and large institutions have $259M invested in Adaptimmune Therapeutics in 2016 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 13 increasing their positions, 6 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

117% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 6

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

4% more capital invested

Capital invested by funds: $250M → $259M (+$9.01M)

0% more funds holding

Funds holding: 49 → 49 (0)

0% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 12

Holders
49
Holders Change
–
Holders Change %
0%
% of All Funds
1.31%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.05%
New
12
Increased
13
Reduced
6
Closed
12
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
NMC
NEA Management Company
Maryland
+$80.8M
2
Millennium Management
Millennium Management
New York
+$4.68M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$3.98M
4
Baillie Gifford & Co
Baillie Gifford & Co
United Kingdom
+$3.51M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$2.45M

Top Sellers

Rank Fund Capital Flow
1
EAM
EverPoint Asset Management
Connecticut
-$3.92M
2
UBS AM
UBS AM
Illinois
-$2.55M
3
Marshall Wace
Marshall Wace
United Kingdom
-$1.7M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
-$1.57M
5
GTC
Ghost Tree Capital
New York
-$1.31M
Name Holding Trade Value Shares
Change 		Change in
Stake
NMC
1
NEA Management Company
Maryland
$80.3M +$80.8M +9,880,999 New
Fidelity Investments
2
Fidelity Investments
Massachusetts
$57.5M +$3.98M +486,179 +7%
Capital World Investors
3
Capital World Investors
California
$37.4M – – –
FCMI
4
Foresite Capital Management II
California
$14.3M – – –
Adage Capital Partners
5
Adage Capital Partners
Massachusetts
$9.35M +$2.45M +300,000 +35%
Millennium Management
6
Millennium Management
New York
$7.45M +$4.68M +572,075 +166%
QF
7
QVT Financial
New York
$6.37M +$966K +118,079 +18%
RSCM
8
Rock Springs Capital Management
Maryland
$6.22M – – –
Fidelity International
9
Fidelity International
Bermuda
$6.13M – – –
Wellington Management Group
10
Wellington Management Group
Massachusetts
$4.34M -$381K -46,530 -8%
O
11
OrbiMed
New York
$3.57M – – –
Baillie Gifford & Co
12
Baillie Gifford & Co
United Kingdom
$3.49M +$3.51M +429,700 New
Jennison Associates
13
Jennison Associates
New York
$3.28M -$687K -83,981 -17%
TCM
14
Tekla Capital Management
Massachusetts
$2.41M – – –
IHM
15
Iguana Healthcare Management
New York
$2.03M -$844K -103,161 -29%
A
16
Abingworth
United Kingdom
$2.03M – – –
RG
17
Rathbones Group
United Kingdom
$1.63M – – –
OM
18
Opaleye Management
Massachusetts
$1.43M +$1.43M +175,300 New
Renaissance Technologies
19
Renaissance Technologies
New York
$920K +$686K +83,900 +286%
WMSA
20
Weiss Multi-Strategy Advisers
New York
$894K +$57.3K +7,000 +7%
Zurich Cantonal Bank
21
Zurich Cantonal Bank
Switzerland
$858K +$863K +105,476 New
BBA
22
Baker Bros. Advisors
New York
$813K – – –
DCM
23
DAFNA Capital Management
California
$716K +$327K +40,000 +83%
State Street
24
State Street
Massachusetts
$535K – – –
RIM
25
RS Investment Management
California
$512K – – –
1
2 3

ADAP Hedge Fund Activity: Q1 2016 in Review

49 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in Adaptimmune Therapeutics (ADAP) for Q1 2016, worth a combined $259M — up 3.6% from $250M a quarter earlier.

Fund positioning in ADAP was balanced in Q1 2016: 12 funds opened new positions, 12 closed out, 13 added to existing stakes and 6 trimmed.

The largest buyer was NEA Management Company, opening a new position worth an estimated $80.8M. The largest seller was EverPoint Asset Management, exiting entirely with an estimated $3.92M sold.

  • 49 institutional investors held Adaptimmune Therapeutics (ADAP) as of Q1 2016, unchanged from Q4 2015.
  • Funds reported $259M of Adaptimmune Therapeutics stock for Q1 2016, up 3.6% quarter-over-quarter.
  • 12 funds opened new Adaptimmune Therapeutics positions in Q1 2016 and 12 closed out, a net change of 0 holders.
  • The largest Adaptimmune Therapeutics buyer in Q1 2016 was NEA Management Company, an estimated $80.8M added.
  • The largest Adaptimmune Therapeutics seller in Q1 2016 was EverPoint Asset Management, an estimated $3.92M sold.

Based on aggregated 13F filings for Q1 2016.